![nanox imaging stock nanox imaging stock](https://www.geektime.com/content/images/2021/08/Screen_Shot_2021-08-10_at_11.06.08.jpg)
On June 17, 2021, Nano-X submitted a 510(k) submission to the U.S. Investors have until Decemto apply to the Court to be appointed as lead plaintiff in the lawsuit. (“Nano-X” or the “Company”) (NASDAQ: NNOX) in the United States District Court for the Eastern District of New York on behalf of all persons and entities who purchased or otherwise acquired Nano-X securities between Jand August 18, 2021, both dates inclusive (the “Class Period”). View source version on businesswire.Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, reminds investors that a class action lawsuit has been filed against Nano-X Imaging Ltd. Prior results do not guarantee similar outcomes. For more information about the firm, please visit Attorney advertising. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. is a nationally recognized law firm with offices in New York, California, and South Carolina. There is no cost or obligation to you.īragar Eagel & Squire, P.C. Raymond by email at telephone at (212) 355-4648, or by filling out this contact form.
![nanox imaging stock nanox imaging stock](https://dailyalts.com/wp-content/uploads/2020/06/screenshot-www.nanox_.vision-2020.06.05-15_45_25.png)
![nanox imaging stock nanox imaging stock](https://investmentu.com/wp-content/uploads/2020/08/shutterstock_1197120079.jpg)
If you purchased or otherwise acquired Nano-X shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Alexandra B. due within 180 days from the date of the request for additional information.” On this news, Nano-X’s ordinary share price fell nearly 10%, damaging investors. On August 19, 2021, Nano-X reported that Nano-X “received a request for additional information from the concerning the Company’s last 510(k) submission of its multi-source device, Nanox.ARC,” and that “he submission file is placed on hold pending a complete response to the FDA’s list of deficiencies,” with “he Company’s response. ARC’s regulatory and commercial prospects and (iv) consequently, Nano-X’s public statements were materially false and misleading at all relevant times. The Nano-X class action lawsuit alleges that, throughout the Class Period, defendants made false and misleading statements and failed to disclose that: (i) Nano-X’s 510(k) application for the Nanox.ARC was deficient (ii) accordingly, it was unlikely that the FDA would approve the 510(k) application for the Nanox.ARC in its current form (iii) as a result, Nano-X had overstated the Nanox. Securities and Exchange Commission filings. Following this submission, defendants touted the Nanox.ARC’s regulatory and commercial prospects in various public statements and U.S. A 510(k) is a type of premarket submission made to the FDA to demonstrate that a device to be marketed is as safe and effective, that is, substantially equivalent, to a legally marketed device. Food and Drug Administration (the "FDA") for its multi-source version of the Nanox.ARC. Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, reminds investors that a class action lawsuit has been filed against Nano-X Imaging Ltd.